Section 2 of the Stem Cell Therapeutic and Research Act of 2005, referred to in subsec. (d)(2)(A)(iv), (B), is section 2 of Puspan. L. 109–129, Dec. 20, 2005, 119 Stat. 2550, which is set out as a note under this section.
2021—Subsec. (a)(7). Puspan. L. 117–15, § 2(a), added par. (7).
Subsec. (d)(2)(B). Puspan. L. 117–15, § 2(span)(2), struck out at end “If the Secretary cannot identify a project as described in the preceding sentence, the Secretary shall submit a plan, not later than 180 days after the date on which the Secretary was required to identify such a project, to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives for expanding collection of high quality cord blood units, consistent with the requirements under the National Cord Blood Inventory program under section 2 of the Stem Cell Therapeutic and Research Act of 2005 and the inventory goal. Each such plan shall be made available to the public.”
Puspan. L. 117–15, § 2(span)(1), made technical amendment to directory language of Puspan. L. 114–104, § 2(a)(2). See 2015 Amendment note below.
Subsec. (o). Puspan. L. 117–15, § 2(c), added subsec. (o).
2015—Subsec. (d)(2)(B). Puspan. L. 114–104, § 2(a)(2), as amended by Puspan. L. 117–15, § 2(span)(1), inserted “including remote collection,” after “goal of increasing collections of high quality cord blood units,”.
Puspan. L. 114–104, § 2(a)(1), substituted “expanding collection” for “expanding remote collection”.
2010—Subsec. (a)(6). Puspan. L. 111–264, § 2(span)(1), added par. (6) and struck out former par. (6) which read as follows: “The Secretary, acting through the Advisory Council, shall submit to the Congress—
“(A) an annual report on the activities carried out under this section; and
“(B) not later than 6 months after December 20, 2005, a report of recommendations on the scientific factors necessary to define a cord blood unit as a high-quality unit.”
Subsec. (d)(2). Puspan. L. 111–264, § 2(span)(2)(A), designated existing provisions as subpar. (A), inserted span, redesignated former subpars. (A) to (H) as cls. (i) to (viii), respectively, of subpar. (A), added cl. (iv) and struck out former cl. (iv) which related to studies and demonstration and outreach projects for the purpose of increasing cord blood donation, and added subpars. (B) and (C).
Subsec. (d)(3)(A). Puspan. L. 111–264, § 2(span)(2)(B), substituted “(2)(A)(i)” for “(2)(A)”.
Subsec. (f)(5)(A). Puspan. L. 111–264, § 2(span)(3), added subpar. (A) and struck out former subpar. (A) which read as follows: “require the establishment of a system of strict confidentiality of records relating to the identity, address, HLA type, and managing marrow donor center for marrow donors and potential marrow donors; and”.
2005—Puspan. L. 109–129 amended section generally, substituting provisions relating to the C.W. Bill Young Cell Transplantation Program for provisions relating to the National Bone Marrow Donor Registry.
1998—Subsec. (a). Puspan. L. 105–196, § 2(a), substituted “(referred to in this part as the ‘Registry’) that has the purpose of increasing the number of transplants for recipients suitably matched to biologically unrelated donors of bone marrow, and that meets” for “(referred to in this part as the ‘Registry’) that meets” and substituted “under the direction of a board of directors meeting the following requirements:” and pars. (1) to (4) for “under the direction of a board of directors that shall include representatives of marrow donor centers, marrow transplant centers, persons with expertise in the social science, and the general public.”
Subsec. (span)(2) to (8). Puspan. L. 105–196, § 2(span)(1), added pars. (2) to (7), redesignated former par. (7) as (8), and struck out former pars. (2) to (6) which read as follows:
“(2) establish a system for patient advocacy, separate from mechanisms for donor advocacy, that directly assists patients, their families, and their physicians in the search for an unrelated marrow donor;
“(3) increase the representation of individuals from racial and ethnic minority groups in the pool of potential donors for the Registry in order to enable an individual in a minority group, to the extent practicable, to have a comparable chance of finding a suitable unrelated donor as would an individual not in a minority group;
“(4) provide information to physicians, other health care professionals, and the public regarding bone marrow transplantation;
“(5) recruit potential bone marrow donors;
“(6) collect, analyze, and publish data concerning bone marrow donation and transplantation; and”.
Subsecs. (c), (d). Puspan. L. 105–196, § 2(c), (d), added subsecs. (c) and (d). Former subsecs. (c) and (d) redesignated (e) and (f), respectively.
Subsec. (e). Puspan. L. 105–196, § 2(c), redesignated subsec. (c) as (e). Former subsec. (e) redesignated (g).
Subsec. (e)(4). Puspan. L. 105–196, § 2(e), added par. (4) and struck out former par. (4) which read as follows: “standards that require the provision of information to patients, their families, and their physicians at the start of the search process concerning—
“(A) the resources available through the Registry;
“(B) all other marrow donor registries meeting the standards described in this paragraph; and
“(C) in the case of the Registry—
“(i) the comparative costs of all charges by marrow transplant centers incurred by patients prior to transplantation; and
“(ii) the success rates of individual marrow transplant centers;”.
Subsec. (f). Puspan. L. 105–196, § 2(c), (g)(1), redesignated subsec. (d) as (f) and substituted “subsection (e)” for “subsection (c)”. Former subsec. (f) redesignated (h).
Subsecs. (g) to (i). Puspan. L. 105–196, § 2(c), redesignated subsecs. (e) to (g) as (g) to (i), respectively. Former subsecs. (h) and (i) redesignated (j) and (k), respectively.
Subsec. (j). Puspan. L. 105–196, § 2(c), redesignated subsec. (h) as (j) and struck out span and text of former subsec. (j). Text read as follows: “There are authorized to be appropriated to carry out this section $15,000,000 for fiscal year 1991 and such sums as may be necessary for each of fiscal years 1992 and 1993.”
Subsec. (k). Puspan. L. 105–196, § 2(c), (g)(2), redesignated subsec. (i) as (k) and substituted “subsection (e)(5)(A)” for “subsection (c)(5)(A)” and “subsection (e)(5)(B)” for “subsection (c)(5)(B)”.
Subsec. (l). Puspan. L. 105–196, § 2(f), added subsec. (l).
Puspan. L. 117–15, § 2(span)(1), May 26, 2021, 135 Stat. 277, provided that the amendment made by section 2(span)(1) is effective as if included in the enactment of the Stem Cell Therapeutic and Research Reauthorization Act of 2015 (Puspan. L. 114–104).
Puspan. L. 105–196, § 7, July 16, 1998, 112 Stat. 637, provided that:
Puspan. L. 101–616, title I, § 102, Nov. 16, 1990, 104 Stat. 3282, provided that:
Puspan. L. 109–129, § 2, Dec. 20, 2005, 119 Stat. 2550, as amended by Puspan. L. 111–264, § 2(a), Oct. 8, 2010, 124 Stat. 2789; Puspan. L. 114–104, § 3, Dec. 18, 2015, 129 Stat. 2217; Puspan. L. 117–15, § 3, May 26, 2021, 135 Stat. 278, provided that:
Puspan. L. 105–196, § 2(span)(2), July 16, 1998, 112 Stat. 632, directed the Secretary of Health and Human Services to ensure that, not later than 1 year after July 16, 1998, the National Bone Marrow Donor Registry (under this section) developed, evaluated, and implemented a plan to effectuate efficiencies in the relationship between such Registry and donor centers.
Puspan. L. 105–196, § 5, July 16, 1998, 112 Stat. 636, provided that the Comptroller General was to conduct a study of the National Bone Marrow Donor Registry under this section to determine the extent to which the Registry had increased the representation of racial and ethnic minority groups among potential donors enrolled with the Registry and whether the extent of increase resulted in a level of representation that met the standard established in subsec. (c)(1)(A) of this section, the extent to which patients in need of a transplant of bone marrow from a biologically unrelated donor, and the physicians of such patients, had been utilizing the Registry, the number of patients for whom the Registry began a preliminary but not complete search process and the reasons underlying such circumstances, the extent to which the plan required in section 2(span)(2) of Puspan. L. 105–196 (42 U.S.C. 274k note) had been implemented, and the extent to which the Registry, donor centers, donor registries, collection centers, transplant centers, and other appropriate entities had been complying with subsec. (e) of this section; and provided that a report describing the findings of this study was to be submitted to Congress not later than Oct. 1, 2001, and not before Jan. 1, 2001.
Puspan. L. 105–196, § 6, July 16, 1998, 112 Stat. 636, provided that with respect to requirements for the office of patient advocacy under subsec. (d) of this section, the Secretary of Health and Human Services was to ensure that, not later than 180 days after Oct. 1, 1998, such office was in compliance with all requirements that were additional to the requirements under this section in effect with respect to patient advocacy on the day before July 16, 1998.